Management of a 12-Year-Old Female with Viral Illness, Migraines, and a Single Episode of Nocturnal Enuresis
Reassure the family that a single episode of nocturnal enuresis in the context of an acute viral illness does not require specific treatment or investigation.
A single episode of bedwetting during an acute illness is not diagnostic of enuresis and does not warrant intervention. 1 Enuresis is defined as urinary incontinence during sleep in children ≥5 years occurring for at least 3 consecutive months, not as an isolated event. 2, 3
Acute Migraine Management
First-Line Acute Treatment
Prescribe rizatriptan (5–10 mg) combined with ibuprofen (400–600 mg, approximately 10 mg/kg) to be taken simultaneously at migraine onset. 4 This combination is the recommended first-line acute therapy for adolescents with moderate-to-severe migraine. 4
If NSAIDs are contraindicated, substitute acetaminophen (650–1000 mg, approximately 15 mg/kg) for ibuprofen while maintaining the triptan. 4
Instruct the patient to take the combination as soon as moderate headache begins—early administration significantly improves pain relief compared to delayed dosing. 4
Dosing Limits and Medication-Overuse Prevention
The maximum daily rizatriptan dose is 30 mg (three 10-mg doses), with doses spaced at least 2 hours apart. 4
Limit acute medication use to fewer than 10 days per month to prevent medication-overuse headache, which develops when acute treatments are used ≥10 days/month for triptans or ≥15 days/month for NSAIDs. 1, 4
Adding an Antiemetic
- If nausea is prominent, add metoclopramide 10 mg orally at migraine onset to improve symptom control and enhance absorption of the acute migraine medications. 4
Contraindicated Agents
- Never prescribe opioids or butalbital-containing products for acute migraine—these agents are ineffective, carry high risk of dependence, and are strongly associated with medication-overuse headache at a threshold of ≥10 days/month. 4
When to Initiate Migraine Preventive Therapy
Start preventive medication if the patient requires acute treatment ≥2 times per month and experiences ≥3 days of disability. 4 Options include propranolol, topiramate, or amitriptyline, combined with cognitive-behavioral therapy. 4
Anti-CGRP monoclonal antibodies (e.g., erenumab, fremanezumab, galcanezumab) are additional preventive options when first-line agents fail or are not tolerated. 5
Approach to the Single Episode of Nocturnal Enuresis
No Immediate Intervention Required
Inform the family that isolated bedwetting during a viral illness is common and does not constitute a diagnosis of enuresis. 1 The child is likely experiencing transient physiologic stress from the acute infection.
Enuresis requires discrete episodes of urinary incontinence during sleep occurring for at least 3 consecutive months in a child ≥5 years old. 2, 3
If Bedwetting Recurs or Persists
If nocturnal enuresis continues beyond the acute illness and meets diagnostic criteria (≥3 months), then initiate a structured evaluation:
Obtain a detailed voiding history, including daytime urinary frequency, urgency, holding maneuvers, interrupted micturition, weak stream, and any daytime incontinence. 1
Complete a frequency-volume chart (voiding diary) to document daytime voiding patterns and nocturnal urine production. 1, 6
Screen for constipation—ask about stool frequency, consistency, and any discomfort with defecation. Constipation is a common comorbid condition that decreases the chance of successful enuresis therapy. 1
Assess for neuropsychiatric comorbidities (e.g., attention-deficit/hyperactivity disorder), which may contribute to treatment resistance. 1
First-Line Behavioral and Lifestyle Interventions
Counsel the child to void regularly during the day (morning, twice at school, after school, at dinner, and just before bed) and always at bedtime and on awakening. 1
Minimize evening fluid and solute intake while allowing participation in social and sports activities—recommend liberal water intake during the morning and early afternoon, with evening intake ≤200 mL (6 ounces) and no drinking after that until morning. 1
Treat any constipation with the goal of a soft, comfortable bowel movement every day, preferably after breakfast; polyethylene glycol is an evidence-based stool softener (grade Ia evidence). 1
Reassure the family that bedwetting is the fault of neither the child nor the parents, and encourage the child to lead a normal life despite the condition. 1
Pharmacologic Therapy for Persistent Enuresis
Desmopressin (oral tablets 0.2–0.4 mg or oral melt 120–240 mg) is an evidence-based therapy (grade Ia evidence) for monosymptomatic enuresis, with approximately 30% of children achieving full response and 40% partial response. 1
Desmopressin is most effective in children with nocturnal polyuria (nocturnal urine production >130% of expected bladder capacity for age) and normal bladder reservoir function (maximum voided volume >70% of expected bladder capacity for age). 1
Administer desmopressin tablets at least 1 hour before sleep (oral melt tablets 30–60 minutes before bedtime) to achieve maximum renal concentrating effect. 1
Polydipsia is a contraindication to desmopressin—if combined with excessive fluid intake, desmopressin can cause water intoxication with hyponatremia and convulsions. 1 The nasal spray formulation carries higher risk and should be avoided. 1
Alarm Therapy
- Bed alarms are the first-line nonpharmacologic intervention for enuresis but are typically not reimbursed by health insurance. 3 Alarm therapy has higher long-term cure rates than desmopressin but requires sustained motivation and family involvement. 6
Common Pitfalls and Caveats
Do not diagnose enuresis based on a single episode during an acute illness—wait to see if bedwetting persists beyond the viral infection before initiating any evaluation or treatment. 1, 2
Avoid waking the child at night to void as a long-term strategy—this may help for that specific night but does not address the underlying pathophysiology and is not a curative intervention. 1
Do not prescribe triptans to patients with cardiovascular disease (coronary artery disease, prior myocardial infarction, uncontrolled hypertension, or arrhythmias)—use CGRP receptor antagonists (gepants such as rimegepant or ubrogepant) instead. 4
If the rizatriptan-NSAID combination fails after 2–3 treated attacks, switch to a different triptan (e.g., sumatriptan nasal spray or zolmitriptan nasal spray) combined with an NSAID, or consider non-oral triptan formulations for rapid pain spikes. 4